OncoTAb's cutting edge blood test aids breast cancer detection in women with dense breast tissue. Early detection saves lives. OncoTab, Inc. (formerly known as CanDiag, Inc.) is a biotech discovery stage company developing cancer diagnostics and therapeutics based on its tumor associated human MUC1 (tMUC1) epitope technology.
OncoTab, Inc. (formerly known as CanDiag, Inc.) is a biotech discovery stage company developing cancer diagnostics and therapeutics based on its tumor associated human MUC1 (tMUC1) epitope technology.
OncoTab (University of North Carolina at Charlotte spin-out) has in-licensed a technology from the university with applications spanning the life cycle of cancer patients, from detecting and locating cancer to treatment and monitoring for recurrence.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/oncotab-inc-” connections=”true” suffix=””]
OncoTAb has developed an original mouse model system, which allows the discovery of a tumor associated human MUC1 (tMUC1) epitope previously undetected. The tMUC1 antibody (TAB 004) recognizes the altered glycosylated epitope within the MUC1 tandem repeat sequence which were inaccessible in past due to large branches of glycosylation in tumor-associated tMUC1. The antibody binds the target antigen with high binding affinity and does not bind unrelated human MUC1 antigens The TAB004 antibody serves as a platform for diagnostics, imaging and therapeutic agents.
OncoTab has raised close to $1.8 Mn to date and is conducting proof of concept studies that have demonstrated the capability of its platform to specifically target tumors.